Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04716231 | Atacicept in Subjects With IgA Nephropathy | PHASE3 | ACTIVE NOT_RECRUITING | 376 | — | — | Jun 29, 2023 | Jul 1, 2028 | Sep 30, 2025 | 1 | United States |
UPCR based on 24 hour urine collection
| Arm | Type | Description |
|---|---|---|
| Atacicept Dose 150mg | EXPERIMENTAL | Atacicept 150mg once weekly subcutaneous (SC) injections |
| Placebo to match Atacicept (Part C/D) | PLACEBO_COMPARATOR | Placebo to match Atacicept once weekly subcutaneous (SC) injection |
| Name | Type | Description |
|---|---|---|
| Atacicept | BIOLOGICAL | Once weekly subcutaneous (SC) injections by prefilled syringe |
| Placebo to match Atacicept | OTHER | Once weekly subcutaneous (SC) injections by prefilled syringe |
Key Inclusion Criteria: * Must have the ability to understand and sign a written informed consent form * Male or female of ≥18 years of age * Total urine protein excretion ≥1.0 g per 24-hour or urine protein to creatinine ratio (UPCR) ≥1.0 mg/mg based on a 24-hour urine sample during the Screening ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 11 | PHASE3 | BION-1301, LNP023, Atrasentan, Zigakibart, zigakibart |
| Vera Therapeutics, Inc. Class A | VERA | 4 | PHASE3 | Atacicept |
| Travere Therapeutics, Inc. | TVTX | 2 | PHASE3 | sparsentan, irbesartan, Dapagliflozin, Sparsentan |
| Biogen Inc. | BIIB | 1 | PHASE3 | Felzartamab |
| Vertex Pharmaceuticals Incorporated | VRTX | 2 | PHASE3 | Povetacicept |
| AstraZeneca PLC | AZN | 2 | PHASE3 | Ravulizumab |
| Biohaven Ltd. | BHVN | 1 | PHASE1 | BHV-1400 |
| Jade Biosciences, Inc. | JBIO | 1 | PHASE2 | JADE101 |